Prognostic value of HMGNfamily expression in acute myeloid leukemia

Wei Cui; Yuna Liu; Yanan Tan; Xingyue Peng; Longzhen Cui; Zhiheng Cheng; Yifeng Dai; Lin Fu; Tiansheng Zeng; Yan Liu

doi:10.2217/fon-2020-0555

Prognostic value of HMGNfamily expression in acute myeloid leukemia

Wei Cui, Yuna Liu, Yanan Tan, Xingyue Peng, Longzhen Cui, Zhiheng Cheng, Yifeng Dai, Lin Fu, Tiansheng Zeng^*, Yan Liu^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Aim: The objective of this work was to investigate the prognostic role of the HMGN family in acute myeloid leukemia (AML). Methods: A total of 155 AML patients with HMGN1-5 expression data from the Cancer Genome Atlas database were enrolled in this study. Results: In the chemotherapy-only group, patients with high HMGN2 expression had significantly longer event-free survival (EFS) and overall survival (OS) than those with low expression (all p < 0.05), whereas high HMGN5 expressers had shorter EFS and OS than the low expressers (all p < 0.05). Multivariate analysis identified that high HMGN2 expression was an independent favorable prognostic factor for patients who only received chemotherapy (all p < 0.05). HMGN family expression had no impact on EFS and OS in AML patients receiving allogeneic hematopoietic stem cell transplantation. Conclusion: High HMGN2/5 expression is a potential prognostic indicator for AML.

Original language	English
Pages (from-to)	541-548
Number of pages	8
Journal	Future Oncology
Volume	17
Issue number	5
DOIs	https://doi.org/10.2217/fon-2020-0555
Publication status	Published - Feb 2021
Externally published	Yes

Keywords

acute myeloid leukemia
heterogeneity
HMGN2
HMGN5
prognosis

Access to Document

10.2217/fon-2020-0555

Cite this

@article{670ff3627aeb4d449d8a1ee09ee04cde,

title = "Prognostic value of HMGNfamily expression in acute myeloid leukemia",

abstract = "Aim: The objective of this work was to investigate the prognostic role of the HMGN family in acute myeloid leukemia (AML). Methods: A total of 155 AML patients with HMGN1-5 expression data from the Cancer Genome Atlas database were enrolled in this study. Results: In the chemotherapy-only group, patients with high HMGN2 expression had significantly longer event-free survival (EFS) and overall survival (OS) than those with low expression (all p < 0.05), whereas high HMGN5 expressers had shorter EFS and OS than the low expressers (all p < 0.05). Multivariate analysis identified that high HMGN2 expression was an independent favorable prognostic factor for patients who only received chemotherapy (all p < 0.05). HMGN family expression had no impact on EFS and OS in AML patients receiving allogeneic hematopoietic stem cell transplantation. Conclusion: High HMGN2/5 expression is a potential prognostic indicator for AML.",

keywords = "acute myeloid leukemia, heterogeneity, HMGN2, HMGN5, prognosis",

author = "Wei Cui and Yuna Liu and Yanan Tan and Xingyue Peng and Longzhen Cui and Zhiheng Cheng and Yifeng Dai and Lin Fu and Tiansheng Zeng and Yan Liu",

note = "Publisher Copyright: {\textcopyright} 2021 Future Medicine Ltd",

year = "2021",

month = feb,

doi = "10.2217/fon-2020-0555",

language = "English",

volume = "17",

pages = "541--548",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

TY - JOUR

T1 - Prognostic value of HMGNfamily expression in acute myeloid leukemia

AU - Cui, Wei

AU - Liu, Yuna

AU - Tan, Yanan

AU - Peng, Xingyue

AU - Cui, Longzhen

AU - Cheng, Zhiheng

AU - Dai, Yifeng

AU - Fu, Lin

AU - Zeng, Tiansheng

AU - Liu, Yan

PY - 2021/2

Y1 - 2021/2

N2 - Aim: The objective of this work was to investigate the prognostic role of the HMGN family in acute myeloid leukemia (AML). Methods: A total of 155 AML patients with HMGN1-5 expression data from the Cancer Genome Atlas database were enrolled in this study. Results: In the chemotherapy-only group, patients with high HMGN2 expression had significantly longer event-free survival (EFS) and overall survival (OS) than those with low expression (all p < 0.05), whereas high HMGN5 expressers had shorter EFS and OS than the low expressers (all p < 0.05). Multivariate analysis identified that high HMGN2 expression was an independent favorable prognostic factor for patients who only received chemotherapy (all p < 0.05). HMGN family expression had no impact on EFS and OS in AML patients receiving allogeneic hematopoietic stem cell transplantation. Conclusion: High HMGN2/5 expression is a potential prognostic indicator for AML.

AB - Aim: The objective of this work was to investigate the prognostic role of the HMGN family in acute myeloid leukemia (AML). Methods: A total of 155 AML patients with HMGN1-5 expression data from the Cancer Genome Atlas database were enrolled in this study. Results: In the chemotherapy-only group, patients with high HMGN2 expression had significantly longer event-free survival (EFS) and overall survival (OS) than those with low expression (all p < 0.05), whereas high HMGN5 expressers had shorter EFS and OS than the low expressers (all p < 0.05). Multivariate analysis identified that high HMGN2 expression was an independent favorable prognostic factor for patients who only received chemotherapy (all p < 0.05). HMGN family expression had no impact on EFS and OS in AML patients receiving allogeneic hematopoietic stem cell transplantation. Conclusion: High HMGN2/5 expression is a potential prognostic indicator for AML.

KW - acute myeloid leukemia

KW - heterogeneity

KW - HMGN2

KW - HMGN5

KW - prognosis

UR - https://www.scopus.com/pages/publications/85100429270

U2 - 10.2217/fon-2020-0555

DO - 10.2217/fon-2020-0555

M3 - Article

C2 - 33467898

AN - SCOPUS:85100429270

SN - 1479-6694

VL - 17

SP - 541

EP - 548

JO - Future Oncology

JF - Future Oncology

IS - 5

ER -

Prognostic value of HMGNfamily expression in acute myeloid leukemia

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this